financetom
Business
financetom
/
Business
/
Update: Flagstar Financial's Shares Rise After Reporting Q4 Financial Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Flagstar Financial's Shares Rise After Reporting Q4 Financial Results
Jan 30, 2025 9:27 AM

12:03 PM EST, 01/30/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.)

Flagstar Financial's ( FLG/PA ) shares were up more than 17% in recent Thursday trading, after the company reported a Q4 adjusted loss of $0.34 per diluted share, narrowing from a loss of $0.80 a year earlier.

Analysts polled by FactSet expected a loss of $0.54.

Revenue for the quarter ended Dec. 31 was $625 million, compared with $867 million a year earlier.

Analysts surveyed by FactSet expected $558.6 million.

Price: 11.25, Change: +1.65, Percent Change: +17.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Jan 13, 2025
04:32 AM EST, 01/13/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) Teva Pharmaceuticals International subsidiary said Monday it has entered into a collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea, in Israel and Europe, excluding Italy. Financial terms were not disclosed. Klinge has licensed the exclusive global commercialization rights...
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Jan 13, 2025
04:47 AM EST, 01/13/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus. Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of...
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Jan 13, 2025
04:39 AM EST, 01/13/2025 (MT Newswires) -- Illumina ( ILMN ) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson ( JNJ ) , and Novartis ( NVS ) . Under the collaboration, deCODE Genetics will process the samples from the UK...
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
Jan 13, 2025
BAKU, Jan 13 (Reuters) - BP is working to resolve technical problems at the Shah Deniz Alfa (SDA) platform and hopes to resume normal operations as soon as possible, the company told Reuters on Monday. BP suspended work of the platform on Friday after detecting a technical issue at the subsea gas condensate export line between the platform and the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved